APIXABAN CIPLA apixaban 5 mg tablet blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

apixaban, Quantity: 5 mg

Available from:

Cipla Australia Pty Ltd

Pharmaceutical form:

Tablet, film coated

Composition:

Excipient Ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; macrogol 400

Administration route:

Oral

Units in package:

10 tablets, 14 tablets, 28 tablets, 60 tablets

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

APIXABAN CIPLA is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery.,APIXABAN CIPLA is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.,APIXABAN CIPLA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients.,APIXABAN CIPLA is indicated for the prevention of recurrent DVT and PE in adult patients.

Product summary:

Visual Identification: Pink, oval, bocinvex, film-coated tablet plain on both sides; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 10 Months; Container Temperature: Store below 30 degrees Celsius

Authorization status:

Registered